Results 61 to 70 of about 17,219,459 (310)
LAG-3 Expression Predicts Outcome in Stage II Colon Cancer [PDF]
Journal of Personalized Medicine, 2021 Introduction: LAG-3 is an inhibitory immune checkpoint molecule that suppresses T cell activation and inflammatory cytokine secretion. T cell density in the tumor microenvironment of colon cancer plays an important role in the host’s immunosurveillance.
Gaëlle Rhyner Agocs +7 more
openaire +4 more sources
Programmed cell death protein-1 and other inhibitory receptors expressed by regulatory T cells as a restraining factor of checkpoint therapy [PDF]
Archive of OncologyThe effectiveness of anti-PD-1/PD-L1 targeted therapies focused on the antitumor immune response restoration in the treatment of melanoma and several other tumors has renewed trust in immunotherapy potential. Despite inspiring enthusiasm that led both to
Batorov Egor V. +2 more
doaj +1 more source
Therapeutic Advances in Medical Oncology, 2023 Despite major advances with immunotherapy and targeted therapy in the past decade, metastatic melanoma continues to be a deadly disease for close to half of all patients. Over the past decade, advancement in immune profiling and a deeper understanding of
F. Kreidieh, H. Tawbi
semanticscholar +1 more source
Histopathological Evaluation of LAG-3, TIM-3 AND CD38 Levels in Meningiomas
Cam & Sakura Medical Journal, 2021 Objective: Meningiomas are the most common primary intracranial tumors in adults that account for 36% of primary tumors. Treatment options other than surgery and radiotherapy are necessary for meningioma.
Uzay Erdoğan +5 more
doaj +1 more source
An empirical investigation of the relationship between the real economy and stock returns for the United States [PDF]
, 2009 This is the post-print version of the final paper published in the Journal of Policy Modeling. The published article is available from the link below. Changes resulting from the publishing process, such as peer review, editing, corrections, structural ...
Andros Gregoriou +32 more
core +1 more source
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range of Tumors
International Journal of Molecular Sciences, 2022 LAG-3 (Lymphocyte activation gene 3) protein is a checkpoint receptor that interacts with LSEC-tin, Galectin-3 and FGL1. This interaction leads to reduced production of IL-2 and IFN-γ.
N. Sauer +6 more
semanticscholar +1 more source
Клиническая онкогематологияAIM. To analyze the bone marrow lymphocyte subpopulation based on targeted assessment of PD-1, PD-L1, and LAG-3 marker expression in chronic lymphocytic leukemia (CLL) patients with different responses to chemotherapy. MATERIALS & METHODS.
Olesya Nikolaevna Selyutina +7 more
doaj +1 more source
Impact of Technological Innovation Capabilities on the Market Value of Firms [PDF]
, 2009 In the era of globalisation and with the advent of knowledge economies, organisational innovation has assumed a critical role in enhancing economic performance of firms.
Annavarjula, Madan, Mohan, Ramesh
core +2 more sources
bioRxiv, 2022 Novel therapeutic approaches combining immune checkpoint inhibitors are needed to improve clinical outcomes for patients with cancer. Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint molecule that inhibits T-cell activity and antitumor immune
K. Thudium +8 more
semanticscholar +1 more source
Nature MedicineGastroesophageal cancer dynamics and drivers of clinical responses with immune checkpoint inhibitors (ICI) remain poorly understood. Potential synergistic activity of dual programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3 ...
R. Kelly +30 more
semanticscholar +1 more source